Galapagos NV (GLPG)
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biotechnology company, focused on the development and commercialization of novel medicines that will improve people's lives.
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos' most advanced novel mode-of-action program, was discovered using our proprietary target discovery technology, and is being developed by Gielad in Phase 3 in rheumatoid arthritis, Crohn's disease and ulcerative colitis. Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas.
Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ; all with the ticker symbol GLPG.
- Pharmaceuticals & Biotechnology
- 🇳🇱 Netherlands
- €141.70 Friday's close
52 Week High0.0%03 April 2019
52 Week Low0.0%03 April 2019
Next Ex-Div-Date Countdown
|Ex-Div Date||Pay Date||Year||Type||Frequency||Status||Amount|
Galapagos NV optimized dividend - 12 month history
Galapagos NV share price - 12 month history
Try the real thing now:
You currently don't have access this feature, however you can preview the functionality.
This is a fully-functional demo intended to showcase the usefulness of this product using old data.
By proceeding you acknowledge that shown here is old data for demonstration purposes only.
To immediately activate your free account and see the live data you can log in with Facebook or LinkedIn: